Treatment of systemic lupus erythematosus: new therapeutic avenues and blind alleys

OP0116 Effects of Blisibimod, a Subcutaneous Inhibitor of B Cell Activating Factor, in Patients with SLE

(2014) R. Furie et al.   ANNALS OF THE RHEUMATIC DISEASES

SAT0193 Results of a randomized placebo controlled phase ia study of AGS-009, a humanized anti-interferon-α monoclonal antibody in subjects with systemic lupus erythematosus

(2014) I. Tcherepanova et al.   ANNALS OF THE RHEUMATIC DISEASES

LB0003 A Randomized Controlled Study of Laquinimod in Active Lupus Nephritis Patients in Combination with Standard of Care

(2014) D. Jayne et al.   ANNALS OF THE RHEUMATIC DISEASES

Sifalimumab, a Human Anti-Interferon-α Monoclonal Antibody, in Systemic Lupus Erythematosus: A Phase I Randomized, Controlled, Dose-Escalation Study

(2013) Michelle Petri et al.   ARTHRITIS AND RHEUMATISM

Gene-function studies in systemic lupus erythematosus

(2013) José C. Crispín et al.   Nature Reviews Rheumatology

Toll-like receptors as therapeutic targets for autoimmune connective tissue diseases

(2013) Jing Li et al.   PHARMACOLOGY & THERAPEUTICS

Fingolimod Therapy for Multiple Sclerosis

(2013) Mary Willis et al.   SEMINARS IN NEUROLOGY

B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design

(2013) Venkat Reddy et al.   ARTHRITIS RESEARCH & THERAPY

Top 10 Things to Know About Lupus Activity Measures

(2013) Aikaterini Thanou et al.   Current Rheumatology Reports

Treatment of systemic lupus erythematosus: new advances in targeted therapy

(2012) Mindy S. Lo et al.   Annals of the New York Academy of Sciences

Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives - an update

(2012) Newman Yeilding et al.   Annals of the New York Academy of Sciences

Recent insights into the genetic basis of systemic lupus erythematosus

(2012) Ornella Josephine Rullo et al.   ANNALS OF THE RHEUMATIC DISEASES

Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response

(2012) Ronald F van Vollenhoven et al.   ANNALS OF THE RHEUMATIC DISEASES

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus

(2012) Kenneth C. Kalunian et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The lupus nephritis assessment with rituximab study

(2012) Brad H. Rovin et al.   ARTHRITIS AND RHEUMATISM

Abatacept for lupus nephritis: Alternative definitions of complete response support conflicting conclusions

(2012) David Wofsy et al.   ARTHRITIS AND RHEUMATISM

N-acetylcysteine reduces disease activity by blocking mammalian target of rapamycin in T cells from systemic lupus erythematosus patients: A randomized, double-blind, placebo-controlled trial

(2012) Zhi-Wei Lai et al.   ARTHRITIS AND RHEUMATISM

Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon α-kinoid

(2012) Bernard R. Lauwerys et al.   ARTHRITIS AND RHEUMATISM

Emerging therapies for systemic lupus erythematosus — Focus on targeting interferon-alpha

(2012) Eben I. Lichtman et al.   CLINICAL IMMUNOLOGY

Lupus neutrophils

(2012) Jason S. Knight et al.   CURRENT OPINION IN RHEUMATOLOGY

JAK2 inhibition in murine systemic lupus erythematosus

(2012) Clement Tagoe et al.   Immunotherapy

Peptide-based approaches to treat lupus and other autoimmune diseases

(2012) Nicolas Schall et al.   JOURNAL OF AUTOIMMUNITY

Administration of fasudil, a ROCK inhibitor, attenuates disease in lupus-prone NZB/W F1 female mice

(2012) RA Stirzaker et al.   LUPUS

Taming lupus—a new understanding of pathogenesis is leading to clinical advances

(2012) Zheng Liu et al.   NATURE MEDICINE

A Meta-Analysis of Randomized Controlled Trials Comparing Tacrolimus with Intravenous Cyclophosphamide in the Induction Treatment for Lupus Nephritis

(2012) Jin Deng et al.   TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE

Rationale of anti-CD19 immunotherapy: an option to target autoreactive plasma cells in autoimmunity

(2012) Henrik E Mei et al.   ARTHRITIS RESEARCH & THERAPY

Atacicept in combination with MMF and corticosteroids in lupus nephritis: results of a prematurely terminated trial

(2012) Ellen M Ginzler et al.   ARTHRITIS RESEARCH & THERAPY

The Rationale for BAFF Inhibition in Systemic Lupus Erythematosus

(2012) Anne Davidson   Current Rheumatology Reports

Protective Roles of Natural IgM Antibodies

(2012) Caroline Grönwall et al.   Frontiers in Immunology

New Interleukin-23 Pathway Inhibitors in Dermatology

(2011) Marta Kurzeja et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

FTY720-Induced Conversion of Conventional Foxp3−CD4+ T Cells to Foxp3+ Regulatory T Cells in NOD Mice

(2011) Yun Sun et al.   AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY

Safety profile and clinical activity of sifalimumab, a fully human anti-interferon   monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study

(2011) J. T. Merrill et al.   ANNALS OF THE RHEUMATIC DISEASES

Calcium signaling in systemic lupus erythematosus T cells: A treatment target

(2011) Vasileios C. Kyttaris et al.   ARTHRITIS AND RHEUMATISM

B cell biomarkers of rituximab responses in systemic lupus erythematosus

(2011) Edward M. Vital et al.   ARTHRITIS AND RHEUMATISM

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus

(2011) Richard Furie et al.   ARTHRITIS AND RHEUMATISM

First appearance and location of catecholaminergic cells during experimental arthritis and elimination by chemical sympathectomy

(2011) Silvia Capellino et al.   ARTHRITIS AND RHEUMATISM

Beneficial effect of novel proteasome inhibitors in murine lupus via dual inhibition of type I interferon and autoantibody-secreting cells

(2011) H. Travis Ichikawa et al.   ARTHRITIS AND RHEUMATISM

Pharmacokinetics, tolerability, and preliminary efficacy of paquinimod (ABR-215757), a new quinoline-3-carboxamide derivative: Studies in lupus-prone mice and a multicenter, randomized, double-blind, placebo-controlled, repeat-dose, dose-ranging study in

(2011) Anders A. Bengtsson et al.   ARTHRITIS AND RHEUMATISM

Therapeutic blockade of TNF in patients with SLE—Promising or crazy?

(2011) Martin Aringer et al.   AUTOIMMUNITY REVIEWS

Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts

(2011) Cándido Díaz-Lagares et al.   AUTOIMMUNITY REVIEWS

Laquinimod in multiple sclerosis

(2011) Paul S. Giacomini et al.   CLINICAL IMMUNOLOGY

Novel, orally active, proteasome inhibitor, delanzomib (CEP-18770), ameliorates disease symptoms and glomerulonephritis in two preclinical mouse models of SLE

(2011) Matthew M. Seavey et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

Therapeutic strategies for the clinical blockade of IL-6/gp130 signaling

(2011) Simon A. Jones et al.   JOURNAL OF CLINICAL INVESTIGATION

Interferon Alpha as a Primary Pathogenic Factor in Human Lupus

(2011) Timothy B. Niewold   JOURNAL OF INTERFERON AND CYTOKINE RESEARCH

A Phase III, Randomized, Controlled Trial of the Fully Human IL-12/23 mAb Briakinumab in Moderate-to-Severe Psoriasis

(2011) Kenneth B. Gordon et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial

(2011) Sandra V Navarra et al.   LANCET

Assessment of flares in lupus patients enrolled in a phase II/III study of rituximab (EXPLORER)

(2011) JT Merrill et al.   LUPUS

Neutrophils Activate Plasmacytoid Dendritic Cells by Releasing Self-DNA-Peptide Complexes in Systemic Lupus Erythematosus

(2011) R. Lande et al.   Science Translational Medicine

The efficacy and safety of abatacept in patients with non-life-threatening manifestations of systemic lupus erythematosus: Results of a twelve-month, multicenter, exploratory, phase IIb, randomized, double-blind, placebo-controlled trial

(2010) J. T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Targeted tumor necrosis factor receptor I preligand assembly domain improves skin lesions in MRL/lpr mice

(2010) Guo-Min Deng et al.   ARTHRITIS AND RHEUMATISM

Tocilizumab in systemic lupus erythematosus: Data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study

(2010) Gabor G. Illei et al.   ARTHRITIS AND RHEUMATISM

Suppression of autoimmunity and organ pathology in lupus-prone mice upon inhibition of calcium/calmodulin-dependent protein kinase type IV

(2010) Kunihiro Ichinose et al.   ARTHRITIS AND RHEUMATISM

A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus

(2010) Edna Mozes et al.   AUTOIMMUNITY REVIEWS

FTY720 exerts a survival advantage through the prevention of end-stage glomerular inflammation in lupus-prone BXSB mice

(2010) Seiichiro Ando et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Anti-CD40L Immune Complexes Potently Activate Platelets In Vitro and Cause Thrombosis in FCGR2A Transgenic Mice

(2010) L. Robles-Carrillo et al.   JOURNAL OF IMMUNOLOGY

The future of CD20 monoclonal antibody therapy in B-cell malignancies

(2010) Myron S. Czuczman et al.   LEUKEMIA & LYMPHOMA

T cells as therapeutic targets in SLE

(2010) José C. Crispín et al.   Nature Reviews Rheumatology

Pathogenesis of ankylosing spondylitis

(2010) Lai-Shan Tam et al.   Nature Reviews Rheumatology

The role of defective clearance of apoptotic cells in systemic autoimmunity

(2010) Luis E. Muñoz et al.   Nature Reviews Rheumatology

Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus

(2010) F. Catapano et al.   NEPHROLOGY DIALYSIS TRANSPLANTATION

Clinical trials in lupus: what have we learned so far?

(2010) I. N. Bruce et al.   RHEUMATOLOGY

Sphingosine-1-phosphate and immune regulation: trafficking and beyond

(2010) Hongbo Chi   TRENDS IN PHARMACOLOGICAL SCIENCES

A retrospective seven-year analysis of the use of B cell depletion therapy in systemic lupus erythematosus at university college london hospital: The first fifty patients

(2009) Tim Y.-T. Lu et al.   ARTHRITIS AND RHEUMATISM

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus

(2009) Daniel J. Wallace et al.   ARTHRITIS AND RHEUMATISM

Novel evidence-based systemic lupus erythematosus responder index

(2009) Richard A. Furie et al.   ARTHRITIS AND RHEUMATISM

Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase ii/iii systemic lupus erythematosus evaluation of rituximab trial

(2009) Joan T. Merrill et al.   ARTHRITIS AND RHEUMATISM

Pimecrolimus 1% cream versus betamethasone 17-valerate 0.1% cream in the treatment of facial discoid lupus erythematosus: a double-blind, randomized pilot study

(2009) B. Barikbin et al.   CLINICAL AND EXPERIMENTAL DERMATOLOGY

Prevalence of Antinuclear Antibodies in 3 Groups of Healthy Individuals

(2009) Guadalupe G. Marin et al.   JCR-JOURNAL OF CLINICAL RHEUMATOLOGY

An exploratory dose-escalating study investigating the safety, tolerability, pharmacokinetics and pharmacodynamics of intravenous atacicept in patients with systemic lupus erythematosus

(2009) C Pena-Rossi et al.   LUPUS

What does the death of Riquent™ hold for the future of SLE?

(2009) Joan T. Merrill et al.   Nature Reviews Rheumatology

Abetimus sodium for renal flare in systemic lupus erythematosus: Results of a randomized, controlled phase III trial

(2008) Mario H. Cardiel et al.   ARTHRITIS AND RHEUMATISM